Obermatt

Kissei Pharmaceutical

TYO:4547 · JP3240600001
PharmaceuticalsMedium

360

62
EV / EBIT16
Price / Owner Earnings46
Owner Earnings Yield87
Dividend Yield97
Price/Sales44
EV / Gross Profit84
Price/Book95
Return on Capital33
Cash Return on Capital58
Return on Equity55
EBIT Margin19
Gross Profitability37
Cash Conversion12
Accruals56
Owner Earnings Margin69
Sales growth6
Profit Growth32
Long-Term EPS Growth75
Reinvestment14
Price momentum55
Debt load95
Refinancing46
Debt Payback100
Liquidity4
Analyst ratings29
Opinion Changes50
Price Target Upside28
Market mood38
Value Creation7/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Kissei Pharmaceutical clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryJapan
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeTSE
Founded1946
Employees7
ISINJP3240600001
Last UpdateApr 2, 2026
Index & Theme
NephrologyNeurologyGastroenterologyChronic DiseasesUrologyCardiovascularHematologyOncologyAgricultureBiotechnologyFood and Beverage

Description

Analysis

Middle-of-the-road

Kissei Pharmaceutical Co., Ltd. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is attractive. You pay 11.2× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone. At today's price, the market is assuming roughly -2% yearly growth; analysts expect 6%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is sturdy. The company scores 7/20 on our value-creation score: creating some value.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
51
2023202420252026

All-time high

83

Jan 2023

All-time low

45

Jan 2024

Average rank

63

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
44
48
55
72
Price/Earnings
73
56
86
47
Price/Book
95
95
78
100
Dividend Yield
97
63
78
88
Value (overall)
96
76
86
85

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Kissei Pharmaceutical with its peers
HUTCHMED (China)
HKG:13
27
CountryHong Kong SAR China
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Yuhan
KSC:000100
32
CountrySouth Korea
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Reyon Pharmaceutical
KSC:102460
16
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Kyongbo Pharmaceutical
KSC:214390
11
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Bora Pharmaceuticals
TAI:6472
27
CountryTaiwan
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Chong Kun Dang
KSC:185750
55
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →